Bosentan - Isotope Labelled Standards
References
FAQ's
References
- Burri, Kaspar; Clozel, Martine; Fischli, Walter; Hirth, Georges; Loeffler, Bernd Michael; Ramuz, Henri, Sulfonamide, preparation and use thereof as medicine and intermediate, F. Hoffmann-La Roche & Co. AG, Switzerland, EP526708B1, October 18, 2000
- Hopfgartner, G.; Vetter, W.; Meister, W.; Ramuz, H., Fragmentation of Bosentan (Ro 47-0203) in ion-spray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ion, Journal of Mass Spectrometry, Volume: 31, Issue: 1, Pages: 69-76, 1996
Frequently Asked Questions
How are Bosentan impurities formed during the manufacturing process?
Bosentan impurities form during manufacturing due to various factors, such as impurities in starting materials, intermediates, reagents, and purification steps.
How are Bosentan impurities identified and characterized?
Bosentan impurities are identified and characterized using various analytical methods, such as HPLC and LC-MS. Mass spectrometry can also help determine the molecular weight of impurities.
Can impurities in Bosentan change over time?
Yes, impurities in Bosentan can change over time due to storage conditions and exposure to light and heat. It is vital to monitor the quality of Bosentan throughout its shelf life to ensure that it remains safe and effective.
What are the temperature conditions required to store Bosentan impurities?
Bosentan impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.